Business Wire (Free subscription) | 07/17/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2008 financial results on Thursday, July 31, 2008 after the financial
IT Conversations (Free subscription) | 07/10/2008
On BioTech Nation, Dr. Moira Gunn speaks with BIO's Jim Greenwood, and Josh Boger from Vertex Pharmaceuticals during the anual International BIO Conference 2008.
mac.ro (Free subscription) | 06/22/2008
Tags: pharmaceuticals , scientists , chemistry , cambridge ma , preferable Scientific Software Analyst European Research Centre — Oxfordshire Vertex Pharmaceuticals Inc. is a global biotechnology company with research sites in Cambridge MA, La ...
Business Wire (Free subscription) | 06/17/2008
SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated and CHDI Foundation, Inc. (CHDI) today announced a new collaboration aimed at developing assays for use in discovering novel
Fiercebiotech (Free subscription) | 06/09/2008
Vertex Pharmaceuticals saw a significant bump in its share price this morning after researchers released new, mid-stage interim data backing telaprevir for hepatitis C. The company is now penciling Read more...
Business Wire (Free subscription) | 06/09/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from a planned
Business Wire (Free subscription) | 06/09/2008
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting
Business Wire (Free subscription) | 06/06/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its
Market Watch (Free subscription) | 06/05/2008
BOSTON (MarketWatch) -- Drug stocks were on the upswing early Thursday as shares of Vertex Pharmaceuticals rallied after analysts at Cowen & Co. upgraded the stock to outperform from neutral. The Amex Pharmaceutical Index rose marginally to 297.3 and the Amex Biotechnology Idex advanced 1.1% to 773.9. Shares of Vertex were up 14% at $32.76. Market Pulse Stories are Rapid-fire, short news bursts on...
The Triangle Business Journal (Free subscription) | 06/03/2008
GlaxoSmithKline has bought the rights to future royalties from HIV drugs from Vertex Pharmaceuticals Inc. for $160 million. (GSK)
The Philadelphia Business Journal (Free subscription) | 06/03/2008
GlaxoSmithKline has bought the rights to future royalties from HIV drugs from Vertex Pharmaceuticals Inc. for $160 million. (GSK)
The Boston Business Journal (Free subscription) | 06/03/2008
Vertex Pharmaceuticals Inc. has sold the rights to future royalties for two HIV drugs it helped develop for $160 million in cash. (GSK)
Business Wire (Free subscription) | 06/03/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has sold its rights to
Business Wire (Free subscription) | 05/16/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its
Business Wire (Free subscription) | 05/15/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2008 Annual Meeting of Stockholders.
